Share on StockTwits

Stock analysts at Maxim Group initiated coverage on shares of TrovaGene (NASDAQ:TROV) in a report issued on Wednesday, reports. The firm set a “buy” rating on the stock.

TrovaGene (NASDAQ:TROV) traded up 1.79% on Wednesday, hitting $3.41. 42,433 shares of the company’s stock traded hands. TrovaGene has a 1-year low of $3.35 and a 1-year high of $10.27. The stock’s 50-day moving average is $3.65 and its 200-day moving average is $5.16. The company’s market cap is $64.5 million.

TrovaGene (NASDAQ:TROV) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.17) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.23) by $0.06. On average, analysts predict that TrovaGene will post $-0.78 earnings per share for the current fiscal year.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.